IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process Jul 26, 2023 07:05AM
IMV Inc. (IMV) Receives NASDAQ Delisting Notice May 8, 2023 04:31PM
IMV Receives NASDAQ Delisting Notice May 8, 2023 04:30PM
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives May 1, 2023 12:30PM
IMV (IMV) Receives Nasdaq Non-Compliance Notice Mar 31, 2023 04:16PM
View Older Stories

Mar 31, 2023 04:15PM IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Mar 27, 2023 04:16PM IMV Inc. (IMV) Announces Board Changes
Mar 27, 2023 04:15PM IMV Inc. Announces Changes to Its Board of Directors
Mar 16, 2023 07:05AM IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
Mar 9, 2023 07:05AM IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
Feb 13, 2023 07:05AM IMV Inc. (IMV) Reports Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
Feb 13, 2023 07:05AM IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
Jan 9, 2023 04:59AM IMV Inc. (IMV) Provides Update and Planned 2023 Milestones for MVP-S
Jan 8, 2023 05:00PM IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
Dec 15, 2022 07:05AM IMV Inc. (IMV) Reports Initial Data from Phase 2B VITALIZE Trial
Dec 15, 2022 07:05AM IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
Dec 13, 2022 07:05AM IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
Dec 7, 2022 04:14PM IMV Inc. (IMV) Shareholders Approve Reverse Stock Split at 88%
Dec 7, 2022 04:05PM IMV Shareholders Approve Reverse Stock Split at 88%
Nov 25, 2022 04:05PM IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities
Nov 10, 2022 04:05PM IMV Inc. Announces Third Quarter 2022 Financial and Operational Results
Nov 8, 2022 07:05AM IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
Sep 30, 2022 07:05AM IMV Inc. (IMV) Provides an Update on The VITALIZE Trial
Sep 30, 2022 07:05AM IMV Provides an Update on The VITALIZE Trial
Sep 15, 2022 07:45AM IMV Inc. (IMV) Announces Reorganization
Sep 15, 2022 07:45AM IMV Inc. Announces Strategic Reorganization
Sep 1, 2022 07:05AM IMV Inc. to Present at Two Investor Conferences in September
Aug 11, 2022 07:05AM IMV Inc. Announces Second Quarter 2022 Financial and Operational Results
Aug 4, 2022 07:05AM IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
Jul 8, 2022 04:05PM IMV Inc. (IMV) Receives Nasdaq Minimum Bid Notice
Jul 8, 2022 04:05PM IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Jun 30, 2022 07:05AM IMV Announces Annual and Special Meeting of Shareholders Voting Results
Jun 22, 2022 07:05AM IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility
May 17, 2022 08:05AM IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
May 13, 2022 07:05AM IMV Inc. Announces First Quarter 2022 Financial and Operational Results
May 6, 2022 07:05AM IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022
Apr 28, 2022 07:05AM IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting
Apr 22, 2022 07:05AM IMV Inc. Names Michael P. Bailey Chairman of The Board
Apr 8, 2022 05:00PM IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
Apr 6, 2022 07:05AM IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
Apr 4, 2022 07:05AM IMV Inc. to Present at Two Upcoming Investor Conferences
Mar 17, 2022 07:05AM IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
Mar 10, 2022 07:05AM IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022
Mar 9, 2022 07:05AM IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022
Feb 17, 2022 07:05AM IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform
Jan 12, 2022 07:05AM IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL
Jan 5, 2022 07:05AM IMV Inc. to Present at Two Upcoming Investor Events
Dec 22, 2021 07:05AM IMV Inc. (IMV) Appoints Andrew Hall as CEO
Dec 22, 2021 07:05AM IMV Appoints Andrew Hall as Chief Executive Officer
Dec 21, 2021 07:06AM IMV Inc. (IMV) Finalizes Basket Clinical Study in Collaboration with Merck; Reports Promising Top Line Data from the Bladder and MSI-High Cohorts
Dec 21, 2021 07:05AM IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
Dec 20, 2021 07:05AM IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
Dec 2, 2021 07:05AM Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
Nov 30, 2021 07:05AM IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
Nov 23, 2021 08:05AM IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
View Older Stories